← All claims

Gut & Microbiome

joint hypermobility increases irritable bowel syndrome

Contested Gut & Microbiome 🔬 Includes disconfirming
RefutedContestedStrong support
consensus score 0.18

📅 Last reviewed: 2026-07-15

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: Population patterns (Observational)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

3 support 2 contradict 3 tested null 3 mixed · 11 sources, 5 independent groups

What the evidence shows

Joint hypermobility raises the odds of irritable bowel syndrome — connective-tissue laxity / dysautonomia driving intestinal dysmotility.

The evidence (11)

SourceGradeStanceQualityFinding
Silvernale C, Staller K, et al.
2024 · Dig Dis Sci
observational mixed moderate IBS/dyspepsia frequency in JHS/EDS driven substantially by psychological-trauma overlap — partly confounded.
Chan Y et al
2025 · study_type: observational
observational tested-null low hEDS (n=10) vs healthy (n=20), all with IBS/GI symptoms: no significant difference in visceroptosis or correlation with Beighton score.
jh-constipation-2020
2020
observational tested-null low Case-control (children): joint hypermobility significantly more frequent in functional constipation vs controls — supports hypermobility->lower-GI dysmotility (constipation phenotype).
Alsakarneh S et al
2026 · study_type: observational
observational supports high TriNetX propensity-matched EDS vs controls (59,128 pairs): IBS 7.3% in EDS, OR 2.6 (95% CI 2.5-2.8, p<0.001).
Glayzer JE, et al.
2021 · Am J Med Genet C Semin Med Genet
observational contradicts low IBS reported in only 6.5% of 1146 women with EDS/HSD — at or below general-population IBS prevalence (~4–12%), i.e. NO evidence of the elevation the claim predicts.
Sweerts KWE et al
2025 · study_type: observational
observational tested-null low Prospective GI-motility clinic cohort (n=87; HSD n=23 vs non-HSD n=64): no significant differences in GI symptoms or motility patterns across hypermobility/Beighton subgroups.
Choudhary A et al
2025 · study_type: observational
observational mixed moderate hEDS/HSD cohort (n=1044) UMAP-clustered: cluster of n=180 with hEDS/HSD+IBS alone plus a larger IBS+foregut cluster (n=466); no external control group for IBS odds.
Zweig A, et al.
2018 · Neurogastroenterol Motil
observational supports moderate Higher joint-hypermobility prevalence in constipation-predominant IBS (IBS-C) specifically.
Hastings J, Forster JE, Witzeman K
2019 · PM&R
observational supports low G-HSD listed among secondary outcomes as associated with IBS; OR ~4.72 cited by an internal literature survey but NOT present in the official abstract → unverified, full-text-required.
Loganathan P et al
2024 · study_type: observational
observational mixed low Retrospective case series in a GI motility clinic: JHS prevalence 9.7% of 277 patients; among JHS patients, IBS prevalence 55.5%.
Shulman RJ, Self MM, Czyzewski DI, et al.
2020 · J Pediatr
observational contradicts moderate Paediatric comparative study (Beighton >=4 and >=6 thresholds), children with IBS/functional abdominal pain vs controls: 'Beighton scores were SIMILAR between groups, as was the proportion with joint hypermobility.' Beighton scores were unrelated to abdominal pain or stooling characteristics; higher scores tracked with somatisation/depression instead. A purpose-built comparison finding no difference - directly disconfirming.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.